Abstract 4274: Anticancer mechanisms of a small amphipathic molecule, LTX-401, against B16 melanoma cancer cells

Author(s):  
Liv-Marie Eike ◽  
Brynjar Mauseth ◽  
Ketil Camilio ◽  
Oystein Rekdal ◽  
Baldur Sveinbjornsson
Author(s):  
Yoshihiro Ujihara ◽  
Daichi Ono ◽  
Koki Nishitsuji ◽  
Megumi Ito ◽  
Shukei Sugita ◽  
...  

2020 ◽  
Vol 24 (1) ◽  
pp. 22-28
Author(s):  
Riza Apriani ◽  
Fajar Fauzi Abdullah

Kaempferia galanga L. belongs to the family of Zingiberaceae, an endangered medicinal plant with pharmacology activities. Ethyl-p-methoxycinnamate (EPMC) is an essential phytoconstituent of K. galanga rhizomes. Several studies have reported that EPMC has anticancer activities in several cancer cells, including CL-6 gallbladder cancer cells, HepG2liver cancer cells, MCF-7 breast cancer cells, and Raji lymphoma cancer cells. However, studies on A549 lung cancer and B16 melanoma cancer cells have not been reported. This study aimed to determine the anticancer activity of EPMC against A549 lung cancer and B16 melanoma cancer cells. EPMC was obtained by extraction using n-hexane, then recrystallized with chloroform. The isolate was then analyzed by thin-layer chromatography (TLC), and the structure was characterized by Fourier Transform Infrared (FTIR) and Nuclear Magnetic Resonance (NMR) spectroscopy. Cytotoxic activity was determined under Presto Blue assay. Based on the result, EPMC from K. galanga showed the cytotoxic effect on B16 cells with an IC50 value of 97.09 μg/mL, whereas EPMC showed no significant cytotoxic effect on A549 with an IC50 value of 1407.75 μg/mL. It was concluded that EPMC has potential cytotoxic on B16 melanoma cancer cells, but it showed inactive activity against A549 lung cancer cells. Further molecular mechanism underlying EPMC cytotoxic activity needs to be conducted.


2021 ◽  
Vol 124 ◽  
pp. 112086
Author(s):  
Ghazal Farahavar ◽  
Samira Sadat Abolmaali ◽  
Foroogh Nejatollahi ◽  
Amin Safaie ◽  
Sanaz Javanmardi ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Carmela Martini ◽  
Mark DeNichilo ◽  
Danielle P. King ◽  
Michaelia P. Cockshell ◽  
Brenton Ebert ◽  
...  

Abstract Background The formation of blood vessels within solid tumors directly contributes to cancer growth and metastasis. Until recently, tumor vasculature was thought to occur exclusively via endothelial cell (EC) lined structures (i.e. angiogenesis), but a second source of tumor vasculature arises from the cancer cells themselves, a process known as vasculogenic mimicry (VM). While it is generally understood that the function of VM vessels is the same as that of EC-lined vessels (i.e. to supply oxygen and nutrients to the proliferating cancer cells), the molecular mechanisms underpinning VM are yet to be fully elucidated. Methods Human VM-competent melanoma cell lines were examined for their VM potential using the in vitro angiogenesis assays (Matrigel), together with inhibition studies using small interfering RNA and blocking monoclonal antibodies. Invasion assays and adhesion assays were used to examine cancer cell function. Results Herein we demonstrate that CD36, a cell surface glycoprotein known to promote angiogenesis by ECs, also supports VM formation by human melanoma cancer cells. In silico analysis of CD36 expression within the melanoma cohort of The Cancer Genome Atlas suggests that melanoma patients with high expression of CD36 have a poorer clinical outcome. Using in vitro ‘angiogenesis’ assays and CD36-knockdown approaches, we reveal that CD36 supports VM formation by human melanoma cells as well as adhesion to, and invasion through, a cancer derived extracellular matrix substrate. Interestingly, thrombospondin-1 (TSP-1), a ligand for CD36 on ECs that inhibits angiogenesis, has no effect on VM formation. Further investigation revealed a role for laminin, but not collagen or fibronectin, as ligands for CD36 expressing melanoma cells. Conclusions Taken together, this study suggests that CD36 is a novel regulator of VM by melanoma cancer cells that is facilitated, at least in part, via integrin-α3 and laminin. Unlike angiogenesis, VM is not perturbed by the presence of TSP-1, thus providing new information on differences between these two processes of tumor vascularization which may be exploited to combat cancer progression.


2020 ◽  
Vol 10 (2) ◽  
pp. 2117-2125

Cold atmosphere plasma has been shown as a promising technology for certain cancer treatments. In this paper, we report indirect plasma treatment using CAP discharged in cell culture medium and study the effect of identical plasma stimulated culture medium on melanoma cancer cells and fibroblast cells cultured in vitro. The results of MTT assay, migration assay, ROS detection, and alizarin red assay show that plasma-treated medium can have a strong negative effect on melanoma cancer cells compared with the control group. However, the plasma-treated medium has a less cytotoxic effect on fibroblast cells than that on melanoma cancer cells at the same treatment. This result is attributed to the production of reactive oxygen species in the plasma-treated medium to induce apoptosis and inhibit melanoma cell proliferation and further cell metastasis. According to the results, this study shows the potential of CAP plasma treatment for anti-cancer therapy.


Polyhedron ◽  
2020 ◽  
Vol 191 ◽  
pp. 114807
Author(s):  
Jessica Andreza Oliveira Rodrigues ◽  
João Gomes de Oliveira Neto ◽  
Aline Oliveira da Silva de Barros ◽  
Alejandro Pedro Ayala ◽  
Ralph Santos-Oliveira ◽  
...  

EBioMedicine ◽  
2020 ◽  
Vol 58 ◽  
pp. 102902 ◽  
Author(s):  
Agnese Kocere ◽  
Julien Resseguier ◽  
Jens Wohlmann ◽  
Frode Miltzow Skjeldal ◽  
Shanawaz Khan ◽  
...  

2008 ◽  
Vol 25 (3) ◽  
pp. 241-252 ◽  
Author(s):  
Jean A. Engbring ◽  
Rydhwana Hossain ◽  
Sherilyn J. VanOsdol ◽  
Benjamin Kaplan-Singer ◽  
Michael Wu ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document